Atossa Therapeutics' primary focus is on developing innovative therapies for breast cancer. This segment includes the development of (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM), which is currently undergoing clinical trials. Research and development efforts are directed towards optimizing (Z)-endoxifen's efficacy and safety profile, as well as exploring its potential in various breast cancer subtypes and stages. The company is also investigating synergistic compounds that may enhance the effectiveness of (Z)-endoxifen. This segment aims to provide more effective and less toxic treatment options for breast cancer patients, addressing the unmet needs in endocrine therapy and prevention.

Atossa Therapeutics is also engaged in developing therapies for infectious diseases, particularly focusing on COVID-19. This segment includes the development of AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19, and AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients. Research and development efforts are directed towards evaluating the safety and efficacy of these therapies in clinical trials. The company aims to provide effective and accessible treatment options for COVID-19 patients, addressing the ongoing needs in managing the pandemic.